Redefining the standard for ultra-sensitive and early MRD detection
Pathlight™ is a blood-based, multi-cancer MRD test that enables clinicians to monitor cancer progression from early detection through relapse and metastasis—supporting confident, informed treatment decisions at every stage of care.
Redefining the standard for ultra-sensitive and early MRD detection
Pathlight™ is a blood-based, multi-cancer MRD test that enables clinicians to monitor cancer progression from early detection through relapse and metastasis—supporting confident, informed treatment decisions at every stage of care.
Breaking barriers in clinical performance
With its first indication in breast cancer, Pathlight has been shown to deliver a 96% detection rate at baseline (pre-treatment) across all stages and subtypes, 94% in estrogen receptor-positive (ER+) breast cancer – a patient population in which first-generation MRD tests struggle to exceed 80%.
In a published study1, Pathlight delivered 100% sensitivity, 100% specificity and a 13.7-month lead time, a powerful advantage for detecting recurrence early.
Pathlight also breaks the 1ppm sensitivity barrier – enabling the detection of early, small tumors while they’re still treatable.
%
sensitivity
month lead time
%
specificity
A personalized test powered by unparalleled knowledge of each tumor's source code
First-generation MRD tests rely on detecting single nucleotide variants (SNVs), which are susceptible to technical noise, leading to false positives that impact specificity and false negatives that decrease sensitivity, leading to shorter lead times across many tumor types.
Pathlight works differently by focusing on large-scale genomic alterations called structural variants (SVs) that are patient- and tumor-specific. SVs are much less susceptible to detection noise. This results in a test with 20x greater analytical sensitivity1 than first-generation MRD assays, and 100% analytical and clinical specificity.
Fast answers.
Meaningful impact.
Every cancer diagnosis comes with unknowns. Pathlight delivers trusted insights that enable better informed treatment decisions by physicians and patients.
Personalized tumor fingerprint development and initial blood test: results will be available 3-4 weeks from receipt of both tissue and blood at the laboratory.
Subsequent blood tests: results will be available 3- 5 days from receipt of blood at the laboratory.
Robust performance across multiple solid tumor types.
Proven in clinical studies including top-tier pharma companies and leading US cancer centers.
Order a Pathlight test
Setting up your account and ordering kits is easy. Please contact our client services team to create your clinician account and start ordering Pathlight for your patients.
References
- Elliott MJ, Howarth K, Main S, et al. Ultrasensitive detection and monitoring of circulating tumor DNA using structural variants in early-stage breast cancer. Clin Cancer Res. Published online January 7, 2025. doi:10.1158/1078-0432.CCR-24-3472